Australia markets closed

Corcept Therapeutics Incorporated (0I3Q.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
22.89+0.09 (+0.39%)
At close: 06:50PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.48
52-week change 314.89%
S&P500 52-week change 320.07%
52-week high 334.12
52-week low 30.00
50-day moving average 323.44
200-day moving average 326.00

Share statistics

Avg vol (3-month) 32.32k
Avg vol (10-day) 3705
Shares outstanding 5115.47M
Implied shares outstanding 6N/A
Float 884.83M
% held by insiders 111.41%
% held by institutions 186.11%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 22.00%
Operating margin (ttm)23.39%

Management effectiveness

Return on assets (ttm)11.13%
Return on equity (ttm)21.05%

Income statement

Revenue (ttm)482.38M
Revenue per share (ttm)4.66
Quarterly revenue growth (yoy)31.40%
Gross profit (ttm)N/A
EBITDA 108.32M
Net income avi to common (ttm)105.5M
Diluted EPS (ttm)0.91
Quarterly earnings growth (yoy)88.90%

Balance sheet

Total cash (mrq)368.22M
Total cash per share (mrq)3.56
Total debt (mrq)151k
Total debt/equity (mrq)0.03%
Current ratio (mrq)4.39
Book value per share (mrq)4.90

Cash flow statement

Operating cash flow (ttm)127.04M
Levered free cash flow (ttm)128.39M